AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached herewith revised press release on the Financial Results for the quarter ended December 31, 2021.03-02-2022
03-02-2022
Earnings Call for Q3FY22 of Aarti Drugs
Conference Call with Aarti Drugs Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.02-02-2022
AARTI DRUGS LTD. - 524348 - Fixes Record Date for Interim Dividend
Aarti Drugs Ltd has informed BSE that the Company has fixed February 10, 2022 as the Record Date for the purpose of Payment of Interim Dividend.01-02-2022
Q3FY22 Quarterly Result Announced for Aarti Drugs Ltd.
Pharmaceuticals company Aarti Drugs declares Q3FY22 result: Margins and Profitability improves sequentially driven by volume growth and improved product mix Specialty Chemicals revenue grew 74% and 62% on a YoY and QoQ basis, respectively Consolidated Highlights Revenue stood at Rs 641.5 crores as against Rs 532.3 crores, a growth of 20.5% YoY. EBITDA stood at Rs 96.7 crores as against Rs 107.8 crores YoY. EBITDA Margin (%) came in at 15.1%. PAT stood at Rs 58.3 crores as against Rs 67.8 crores YoY. PAT Margin (%) came in at 9.1%. Revenue from operations stood at Rs 1,802.7 crores as against Rs 1,656.6 crores, up 8.8% YoY. EBITDA stood at Rs 251.8 crores as against Rs 359.7 crores YoY. EBITDA Margin (%) came in at 14.0%. PAT stood at Rs 149.7 crores as against Rs 228.5 crores YoY. PAT Margin (%) came in at 8.3%. Standalone Highlights Standalone Q3 revenue stood at Rs 579.9 crores. The standalone business contributed 91% to the consolidated revenue for the quarter. 59% of the revenues came from the domestic market and 41% from the exports market for Q3FY22 for a standalone business. API volumes grew considerably at 12%, led by secular growth across acute as well as chronic therapies. Increase in the contribution by chronic therapies led to improvement in product mix, which in turn improved the margins and profitability. Domestic revenue grew approximately by 4% while exports grew by around 19% year-on-year for Q3FY22. Within the API segment, the antibiotic therapeutic category contributed around 46%, antiprotozoal around 16%, anti-inflammatory around 10%, anti-diabetic around 14%, antifungal around 10% and the rest contributed around 5% to total API sales for Q3FY22. Commenting on the results Mr. Adhish Patil, Chief Financial Officer – Aarti Drugs Limited said, “The company posted robust growth in revenue and profitability along with considerable improvement in the margins on a sequential basis. This robust performance was posted despite the multiple headwinds in terms of high raw material prices, high freight costs and coal prices. The margin expansion is primarily driven by proactive price hikes, secular API volume growth across therapies and strict cost control. The volume growth is expected to accelerate further, on the back of recently commissioned anti-diabetics capacity. As a result, the growth trajectory in the API segment is expected to accelerate in line with the volume growth in the upcoming quarters. This coupled with a growing share of niche products in chronic therapies and a strong API product launch pipeline is expected to augment the margin profile and profitability. The company witnessed a healthy growth in Specialty Chemicals and Intermediates both on a YoY as well as a sequential basis. A unique value proposition, niche product profile and upcoming capacities in chloro-sulphonation products are expected to bolster the growth momentum further." Result PDF01-02-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached herewith Q3FY22 Results presentation of the Company for your records.31-01-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached herewith press release on the Financial Results for the quarter ended December 31, 2021.31-01-2022
AARTI DRUGS LTD. - 524348 - Corporate Action-Board approves Dividend
We wish to inform you that Board of Directors of the Company at its Meeting held on Monday, January 31, 2022, has declared the Interim Dividend Rs. 1/- (Rupee One) (@10%) per Equity share for the financial year 2021-22. Please note that as per Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, Thursday, February 10, 2022 has been fixed as 'Record Date' for the purpose of payment of Interim Dividend.31-01-2022
AARTI DRUGS LTD. - 524348 - Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31, 2021.
We wish to inform you that Board of Directors at its Meeting held on Monday, January 31, 2022, approved the Audited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021. Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 we enclose the following:- Audited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021. Auditor's Report on Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021.31-01-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Quarterly Conference Call for the Investors and Analysts has been scheduled on Wednesday, February 2, 2022 at 11:00 AM IST to discuss the Company's financial performance for the Quarter and nine months ended December 31, 2021.27-01-2022